|
MechanismcGMP-PDE inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Jan 1997 |
|
MechanismH1 receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date11 Apr 1952 |
100 Clinical Results associated with Wuhan Fuxing Biotechnology Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Wuhan Fuxing Biotechnology Pharmaceutical Co., Ltd.
100 Deals associated with Wuhan Fuxing Biotechnology Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Wuhan Fuxing Biotechnology Pharmaceutical Co., Ltd.